Author's posts
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
For The Asking, A Check Is In The Mail To Help Pay For Costly Drugs
It’s a little-known secret that patients can get thousands of dollars directly from a drugmaker.
Trump Adds A Global Pricing Plan To Wide Attack On Drug Prices, But Doubts Persist
Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.
Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
Trump Administration Sinks Teeth Into Paring Down Drug Prices, On 5 Key Points
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
Trump Administration Sinks Teeth Into Paring Down Drug Prices, On 5 Key Points
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
Top Policy Expert’s Ties To Giant Drugmaker Often Go Unstated
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
